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Objectives: Objective of this study is to evaluate the diagnosis of liver diseases 
among individuals who were detected hepatic dysfunction by the annual health 
checkup (Kenshin) in Japan. MethOds: Annual health checkup data and claims 
data based on Japan Medical Data Center (JMDC) were used to evaluate the diagno-
sis of liver disease by ICD10. Individuals who had annual health checkup in 2012 
and their associated claims data were merged by unique identifiers. Individuals 
(18≤ age≤ 64) with ALT≥ 30(IU/L) were defined as hepatic dysfunction. Confirmed 
diagnoses of liver diseases were evaluated. The time to diagnosis after the annual 
health checkup and the diagnosis with liver disease by ALT levels(IU/L) (30< ALT< 60 
and 60= < ALT) were assessed. Results: Among 57,059 individuals (ALT > 30) with-
out diagnosis of any liver disease in the preceding 12 month of the annual health 
checkup, 7500(13.1%) of individuals were visited physician office within one year 
their after annual health check-ups(30< ALT< 60:5,185 and 60= < ALT:2,315). Among 
individuals visited physician office, 4,379(58.4%) of individuals were diagnosed 
with liver diseases; 30< ALT< 60: 2,733(52.7%) and 60= < ALT: 1,646(71.1%). Fatty 
liver (21.4%) was major diagnosis followed by alcoholic hepatic disease(3.0%), 
virus hepatitis(3.1%), hepatic fibrosis or cirrhosis(0.5%) and liver cancer (0.3%). The 
detection rate of each liver disease are higher in individuals with 60= < ALT com-
pared to individuals with 30< ALT< 60. Time to diagnosis was also faster among 
individual with 60= < ALT compare to individuals with 30< ALT< 60 (log-rank test: 
p < 0.0001). cOnclusiOns: The proportion of individuals diagnosed with liver dis-
ease was relatively low considering the number of individuals with hepatic dysfunc-
tion detected by the annual checkup. Individuals with higher ALT levels were more 
likely to be diagnosed with liver disease.
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Objectives: Through the Italian off-label/compassionate use procedure, regulated 
by Law 648/96, the Technical Committee of AIFA (CTS) can include a given medica-
tion (among innovative drugs authorised abroad, but not in Italy, drugs which have 
not yet received an authorisation but have undergone clinical trials, and drugs to 
be used for a therapeutic indication different from the authorized one) in an official 
list, allowing it to be prescribed at the charge of the National Health System (NHS). 
This study aimed to assess AIFA’s approach, by reviewing approvals, rejections and 
methods followed by AIFA for its decisions. MethOds: Reports of CTS meetings 
from January 2013 to May 2015 were reviewed, checking number and characteristics 
of drugs under evaluation, and analyzing each single decision taken by CTS. The 
impact of 648 on pricing and reimbursement decisions was also analysed (both in 
terms of price and time) Results: Out of 103 applications, 37 (35,9%) received a 
positive evaluation, 54 (52,4%) a negative evaluation and 12 (11,7%) a conditional 
approval. The main therapeutic areas represented were oncology/onco-haematology 
with 29 requests (28,2%), followed by paediatrics with 12 requests (9,2%), non-onco-
logical haematology and cardiovascular, both with 9 requests (6,9% each), neurology 
and ophthalmology. Several rare disease compounds have been evaluated. Analysis 
indicated that the drivers for the inclusion in the 648 List were the presence of 
strong clinical data, the lack of therapeutics alternatives in the Italian market, the 
rare disease condition and the paediatric indication. cOnclusiOns: In the last 
two-and-a-half years, 49 indications have been approved, ensuring new important 
safe and efficacious therapeutic options. This analysis shows the important role of 
the Italian Law 648/96, a precious tool for patients to be treated with a drug, with 
strong clinical and safety data, waiting for the whole Italian regulatory process to 
be completed.
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Objectives: Over the past decade, the European Medicines Agency (EMA) has 
granted regulatory approval to over 75 rare disease therapies and acknowledged 
hundreds of pipeline compounds with rare disease regulatory designation. In 
Europe, market access for new technologies is predominantly dependent on regu-
latory and country-specific health technology assessments. Therefore, the purpose 
of this analysis was to examine how the impact of United Kingdom (UK) health 
policies affected the market access of rare disease technologies during 2005-
2014. MethOds: A list of approved rare disease health technologies was con-
structed utilizing publically available data from the EMA. The technologies had to 
adhere to European specific rare disease designation guidelines for study inclusion. 
Secondly, the list was cross-referenced with the National Institute of Health and 
Care Excellence (NICE) repository of appraised technologies. Information extracted 
from the NICE repository included: complete appraisal document, incremental cost-
effectiveness ratio (ICER), and final agency recommendation. Thirdly, an Excel work-
sheet was created and several descriptive techniques were used for trend analysis, 
including: calculating the proportion of NICE appraisal of EMA approvals, EMA/
NICE annual approval rate, and ICER range across NICE appraisals. Results: A 
Positive trend in rare disease technology regulatory approvals from 2005-2014 was 
observed in Europe (average increase of 1.2 approvals/year), with the highest number 
of approvals occurring in 2014 (total approvals = 15). The trend in NICE approv-
als during this period remained flat at an average of 0.2/year (5 currently under 
review in 2014), despite the number of appraisals increasing an average of 0.5/year. 
Objectives: Anaemia is a frequent complication among patients with Chronic 
Kidney Disease (CKD). This retrospective, observational study quantifies health-
care resource utilization (HCRU) and costs associated with anaemia in an Italian 
cohort of CKD-NOD patients. MethOds: Administrative data and clinical laboratory 
files of 7 Italian LHUs from 2006 and 2011 were used to identify patients with CKD 
(stage3b, 4, 5) and anaemia. Included patients had anaemia (≥ 2 haemoglobin [Hb] 
measurements 1 week–3 months apart < 13 g/dL for males, < 12 g/dL for females) 
associated with CKD-NOD stage 3b, 4, or 5. HCRU included CKD-anaemia medica-
tions, laboratory tests, haematologist/cardiologist visits, and hospitalisations for 
CKD-anaemia or cardiovascular disease (CVD). Costs were calculated using Italian 
prices and tariffs. Results: 1,654 patients were included. Overall, 542 (32.8%) of all 
1,654 patients received anaemia medications during follow-up. The prevalence of 
anaemia medication use and number of prescriptions for these medications were 
higher at higher CKD stage, although the low numbers of patients in stage 5 (from 
28.3% for stage 3b to 55.3.% for stage 5). ESAs were prescribed to 85.7% of CKD stage 
5 patients whereas CKD stage 3b patients received mostly oral iron (60.2%). Patients 
receiving any anaemia-related medications had lower per patient-per year cost 
for all studied resources compared to patients not receiving any medications. For 
anaemia-related outpatient services [treated and not treated]: stage 3b costs per 
patient year were € 61.86 and € 65.46 respectively; € 60.79 and € 73.31 for stage 4; € 63.40 
and € 81.26 for stage 5. For general visits: € 175.87 and € 194.61 for stage 3b; € 152.32 
and € 186.73 for stage 4; € 152.36 and € 342.09 for stage 5. For CV hospitalizations costs 
were € 1531.91 and € 1740.88 for stage 3b; € 1,152.27 and € 2,194,06 for stage 4; € 527.79 
and € 483.44 for stage 5. cOnclusiOns: Anaemia management may help lower both 
anaemia-related outpatient services and CV complications costs.
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Objectives: To assess the consumption of healthcare resources in patients with 
polycystic kidney disease, and analyse related costs MethOds: Database analysis of 
administrative databases, containing information on beneficiaries of two Local Health 
Units, for around 2 million subjects. Data from all patients with polycystic kidney 
disease in the period January 2010 - December 2012 were analysed, the index-date 
was the date of diagnosis at hospitalisation; for patients on dialysis, index-date was 
the first day of dialysis during enrolment period Results: 608 patients with poly-
cystic kidney disease were enrolled (ICD-9 753.1), 11.2% were ADPKD patients. 1.5% 
of patients was ARPKD, in 16.3% genotype was not specified, and in the remaining 
ones the disease had not been classified.These four sub-populations were analysed, 
and the 68 ADPKD patients reported some differences from the overall population 
enrolled. Mean age in ADPKD group was 45.9 years, versus 57 of the entire sample, 
and the incidence of dialysis was 4-fold (29.4% compared to an overall 7.9%).1-year 
consumption of healthcare resources for the 20 dialysed patients with ADPKD was 
higher than in non-dialysed patients: 27.5 drug prescriptions compared to 15.2, and 
27.6 recurrences to ambulatory care services compared to 5.1, respectively.Health 
expenditure for ADPKD dialysed patients was € 36,999.30 per year, € 28,545.30 for 
ambulatory care (96% dialysis-related), € 4’695.45 for hospitalizations and € 3’758.55 
for drugs.For non-dialysed ADPKD patients, total expenditure was € 4’534.79, with € 
2,017.44 for hospitalisations; drugs cost was € 1,998.60 - 5% of which for anti-hyper-
tensives - and ambulatory care services amounted to € 518.75 cOnclusiOns: The 
reported higher incidence of dialysis - and a lower mean age - highlight the severity 
of PKD connected to the autosomal dominant type, that eventually leads to an annual 
burden for NHS of about € 37’000 for each ADPKD dialysed patients
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Objectives: To understand current levels of awareness, usage, and knowledge 
of biosimilars. MethOds: Interviews (10 to 20 minutes of close-ended questions) 
were conducted online in adults categorized as: 1) Diagnosed: patients with Crohn’s 
disease, ulcerative colitis, rheumatoid arthritis, psoriasis, breast cancer, lung cancer, 
colorectal cancer, or non-Hodgkin’s lymphoma; 2) Diagnosed Advocacy: individuals 
with these diseases who participated in patient support groups; 3) Caregiver: has a 
loved one with these conditions and is involved in medical decisions; or 4) General 
Population: aged 18 to 64 years without (nor loved ones with) these conditions. 
Groups were analyzed using the column proportions test with a 95% confidence 
interval. Results: A total of 3,198 individuals responded. Awareness about biologic 
therapies, defined as the percentage of respondents reporting at least a general 
impression of biologics or that they knew the term “biologic”, was significantly 
higher in the Diagnosed, Diagnosed Advocacy, and Caregiver groups (45-78%) than 
the General Population (27%; P < 0.05). Across all groups, awareness of biosimilars 
was low with only 6% of respondents from the General Population reporting at least 
a general impression of biosimilars, although this was significantly higher among 
respondents in the Diagnosed Advocacy group (20-30%; P < 0.05). Several gaps in 
respondents’ knowledge about biosimilars were noted including safety, efficacy, and 
access to these agents. Respondents had generally positive perceptions of clinical 
trials although some barriers to participation were identified such as concerns 
about side effects, assignment to placebo rather than an active treatment, and 
time commitments. cOnclusiOns: As more biosimilars are becoming approved, 
this study reinforces that there is still an immediate need to provide education to 
all stakeholders about general biosimilar education and biosimilar clinical trials. 
These efforts will support patient choice and ensure that educated and informed 
decisions are made about the use of biosimilars.
